See more : Chesapeake Financial Shares, Inc. (CPKF) Income Statement Analysis – Financial Results
Complete financial analysis of Anew Medical, Inc. (WENA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anew Medical, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- True Data Inc. (4416.T) Income Statement Analysis – Financial Results
- iShares U.S. Thematic Rotation Active ETF (THRO) Income Statement Analysis – Financial Results
- Avid Bioservices, Inc. (CDMOP) Income Statement Analysis – Financial Results
- Baida Group Co.,Ltd (600865.SS) Income Statement Analysis – Financial Results
- Dusit Thani Freehold and Leasehold Real Estate Investment Trust (DREIT.BK) Income Statement Analysis – Financial Results
Anew Medical, Inc. (WENA)
About Anew Medical, Inc.
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 574.37K | 1.11M |
| Selling & Marketing | 0.00 | -40.38K | 0.00 |
| SG&A | 1.23M | 533.99K | 1.11M |
| Other Expenses | -75.60K | -123.03K | 44.00 |
| Operating Expenses | 1.30M | 657.02K | 1.11M |
| Cost & Expenses | 1.30M | 657.02K | 1.11M |
| Interest Income | 3.36M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 24.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 0.00 | 44.00 |
| EBITDA | -1.30M | -574.23K | -1.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.30M | -657.02K | -1.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.34M | 2.13M | 44.00 |
| Income Before Tax | 2.04M | 1.56M | -1.11M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 690.57K | 322.03K | 0.00 |
| Net Income | 1.35M | 1.23M | -1.11M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.14 | 0.08 | -0.09 |
| EPS Diluted | 0.14 | 0.08 | -0.09 |
| Weighted Avg Shares Out | 9.76M | 14.91M | 12.98M |
| Weighted Avg Shares Out (Dil) | 9.76M | 14.91M | 12.98M |
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Appoints New CFO
Source: https://incomestatements.info
Category: Stock Reports